William Betz, MD
Internal Medicine · Myrtle Beach, SCNPI 1710941133
Payments from drug & device makers
Across 222 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$843
- UCB, Inc.$604
- Novo Nordisk$477
- AbbVie$343
- Amgen$304
- BETA Bionics, Inc.$125
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,93399%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 44 | $843 |
| UCB, Inc. | 36 | $604 |
| Novo Nordisk | 26 | $477 |
| AbbVie | 20 | $343 |
| Amgen(2 entities) | 18 | $304 |
| BETA Bionics, Inc. | 4 | $125 |
| Aurinia Pharma U.S., Inc. | 5 | $108 |
| Novartis | 7 | $95 |
| AstraZeneca(2 entities) | 6 | $95 |
| Boehringer Ingelheim | 5 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| Mallinckrodt Hospital Products Inc. | 4 | $68 |
| Radius Health, Inc. | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Averitas Pharma Inc. | 2 | $54 |
| Abbott | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Bayer | 3 | $41 |
| Corcept Therapeutics | 2 | $40 |
| Lilly USA, LLC | 2 | $32 |
| Merck | 2 | $29 |
| Boston Scientific | 2 | $29 |
| Medicomp Inc | 1 | $23 |
| Vital Connect, Inc | 1 | $22 |
| Electromed, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| GSK | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Cequr Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$125
How this compares
$3,975 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $87,960 |
| JanuviaSitagliptin Phosphate | 44 | $62,437 |
| JardianceEmpagliflozin | 42 | $59,064 |
| OzempicSemaglutide | 32 | $41,916 |
| FarxigaDapagliflozin Propanediol | 39 | $38,394 |
| Repatha SureclickEvolocumab | 27 | $29,539 |
| XareltoRivaroxaban | 20 | $23,528 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,248 |
| Rosuvastatin Calcium | 589 | $8,212 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $7,061 |
| Atorvastatin Calcium | 621 | $6,812 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,745 |
| SynthroidLevothyroxine Sodium | 84 | $6,424 |
| Levothyroxine Sodium | 423 | $5,242 |
| Pitavastatin Calcium | 11 | $3,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $29 | $62,43744 claims |
| Boehringer IngelheimJardiance | $92 | $59,06442 claims |
| AstraZenecaFarxiga, Symbicort | $95 | $45,13963 claims |
| Novo NordiskOzempic | $477 | $41,91632 claims |
| Johnson & JohnsonXarelto | $843 | $23,52820 claims |
| GSKTrelegy Ellipta | $13 | $8,24813 claims |
| AbbVieSynthroid | $343 | $6,42484 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Myrtle Beach
- Edward Botse-BaidooMyrtle Beach$90K
- James IserniaMyrtle Beach$69K
- Sarah AllenMyrtle Beach$17K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.